While one in seventy-eight women will face ovarian cancer in her lifetime, this "silent" disease often remains hidden until its advanced stages, presenting a complex global health challenge marked by startling statistics and disparities.
Key Takeaways
- In 2023, an estimated 19,880 new cases of ovarian cancer will be diagnosed in the United States among women
- Globally, ovarian cancer accounted for 313,959 new cases in 2020, representing 3.3% of all new cancer cases in women
- The age-adjusted incidence rate of ovarian cancer in the US was 10.6 per 100,000 women per year based on 2017–2021 data from SEER
- Having a first-degree relative with ovarian cancer increases risk 3- to 5-fold
- BRCA1 mutation carriers have a 39-46% lifetime risk of ovarian cancer
- Postmenopausal hormone therapy (estrogen-only) increases ovarian cancer risk by 24% with long-term use
- Bloating is reported in 75-80% of advanced ovarian cancer patients
- Pelvic pain occurs in 50-60% of women with ovarian cancer at diagnosis
- CA-125 is elevated (>35 U/mL) in 80% of epithelial ovarian cancers
- 5-year survival for stage I ovarian cancer is 90-93%
- Optimal cytoreduction (<1 cm residual) achieved in 75% of cases improves survival to 50 months median
- Platinum-based chemotherapy response rate 70-80% in first-line
- In 2023, an estimated 12,810 ovarian cancer deaths in US women
- Ovarian cancer is 5th leading cause of cancer death in US women, causing 5% of female cancer deaths
- Global ovarian cancer mortality in 2020 was 207,252 deaths
Ovarian cancer affects thousands yearly but early detection remains difficult.
Diagnosis and Symptoms
1Bloating is reported in 75-80% of advanced ovarian cancer patients
Verified2Pelvic pain occurs in 50-60% of women with ovarian cancer at diagnosis
Verified3CA-125 is elevated (>35 U/mL) in 80% of epithelial ovarian cancers
Verified4Ascites is present in 70% of stage III/IV ovarian cancer cases
Directional5Fatigue is a symptom in 70% of patients with ovarian cancer
Single source690% of ovarian cancers are diagnosed at stage III or later due to nonspecific symptoms
Verified7Urinary urgency/frequency reported by 50% of symptomatic women
Verified8HE4 biomarker sensitivity is 85% for ovarian cancer, higher than CA-125 in early stages
Verified9Abdominal distension noted in 60-70% of cases
Directional10Early satiety affects 40-50% of advanced cases
Single source11Transvaginal ultrasound detects 95% of ovarian masses >1 cm
Verified12ROMA index (CA-125 + HE4) has 92% sensitivity for stage I-II epithelial ovarian cancer
Verified13Weight loss occurs in 30-40% of ovarian cancer patients at diagnosis
Verified14Back pain is a symptom in 25-35% of cases
Directional15CT scan has 90% accuracy for staging ovarian cancer
Single source16RMI (Risk of Malignancy Index) score >200 has 87% sensitivity and 89% specificity
Verified17Constipation/diarrhea in 25% of patients
Verified18PET-CT improves staging accuracy to 90-95% in ovarian cancer
Verified19Dyspnea from pleural effusion in 20-30% advanced cases
Directional20Biopsy confirms diagnosis in 95% of cases
Single source21IOTA simple rules classify benign vs malignant masses with 95% accuracy
Verified22Postmenopausal bleeding rare (5%) but concerning in ovarian ca
Verified23MRI has 92% sensitivity for peritoneal spread detection
Verified24Anemia present in 40% at diagnosis due to chronic disease
Directional25Symptom index (GO model) positive in 80% of cases vs 20% controls
Single source26Leg swelling (lymphedema) in 10-15% advanced disease
Verified27OVA1 test (multibiomarker) 99% negative predictive value
VerifiedDiagnosis and Symptoms Interpretation
This symphony of seemingly ordinary complaints, from bloating to back pain, often plays its quiet, misleading overture for far too long before the harsh truth of an advanced ovarian cancer diagnosis finally takes the stage.
Epidemiology
1In 2023, an estimated 19,880 new cases of ovarian cancer will be diagnosed in the United States among women
Verified2Globally, ovarian cancer accounted for 313,959 new cases in 2020, representing 3.3% of all new cancer cases in women
Verified3The age-adjusted incidence rate of ovarian cancer in the US was 10.6 per 100,000 women per year based on 2017–2021 data from SEER
Verified4In Europe, the incidence rate of ovarian cancer varies from 9.3 per 100,000 in Eastern Europe to 12.6 per 100,000 in Northern Europe as of 2020 data
Directional5Among white women in the US, the ovarian cancer incidence rate is 11.0 per 100,000 compared to 8.4 per 100,000 for Black women (2017-2021 SEER data)
Single source6Lifetime risk of developing ovarian cancer for US women is 1 in 78, based on 2018-2021 data
Verified7In 2020, China reported 76,423 new ovarian cancer cases, the highest globally
Verified8The incidence of ovarian cancer in women aged 65-74 years in the UK peaked at 28 per 100,000 in 2018
Verified9From 2000 to 2018, ovarian cancer incidence in the US decreased by 1.4% per year on average
Directional10In Australia, ovarian cancer incidence rate was 11.5 per 100,000 women in 2021
Single source11Japan has one of the lowest ovarian cancer incidence rates at 5.9 per 100,000 women (2020 GLOBOCAN)
Verified12In India, ovarian cancer comprises 2.5% of all new cancer cases in women, with 36,768 cases in 2020
Verified13Hispanic women in the US have an ovarian cancer incidence of 9.7 per 100,000 (2017-2021)
Verified14Between 2015 and 2019, ovarian cancer incidence in Canadian women was 8.9 per 100,000
Directional15In Brazil, 18,845 new ovarian cancer cases were estimated for 2023
Single source16Ovarian cancer represents 1.1% of all new cancer cases in US women but 2.5% of cancer deaths
Verified17In South Korea, ovarian cancer incidence increased by 3.2% annually from 2006-2015
Verified18France reported 4,945 new ovarian cancer cases in 2018, with incidence rate of 9.7 per 100,000
Verified19In the US, 75% of ovarian cancer cases are diagnosed at stage III or IV
Directional20Global prevalence of ovarian cancer (5-year) was 1,440,859 cases in 2020
Single source21In Germany, 5,100 new ovarian cancer diagnoses occurred in 2022
Verified22US women aged 55-64 have the highest ovarian cancer incidence at 15.9 per 100,000 (2017-2021)
Verified23In 2022, Italy had 5,036 new ovarian cancer cases among women
Verified24Ovarian cancer incidence in non-Hispanic Asian/Pacific Islander women in US is 7.9 per 100,000
Directional25From 1999-2018, ovarian cancer incidence declined 30% in the US
Single source26In 2020, Russia reported 15,927 new ovarian cancer cases
Verified27UK ovarian cancer incidence rate for women under 50 is 3.6 per 100,000 (2017-2019)
Verified28In 2021, approximately 4,800 women in Canada were diagnosed with ovarian cancer
Verified29Ovarian cancer accounts for 4% of all cancers in women in Poland (2020 data)
Directional30Lifetime risk of ovarian cancer in UK women is 1.3%
Single sourceEpidemiology Interpretation
Though it may seem statistically small, ovarian cancer's global persistence and stealthy late-stage diagnoses demand attention, reminding us that even a one-in-seventy-eight risk is one too many when early detection remains so elusive.
Mortality and Prevention
1In 2023, an estimated 12,810 ovarian cancer deaths in US women
Verified2Ovarian cancer is 5th leading cause of cancer death in US women, causing 5% of female cancer deaths
Verified3Global ovarian cancer mortality in 2020 was 207,252 deaths
Verified4Age-adjusted mortality rate in US 6.3 per 100,000 women (2017-2021 SEER)
Directional5Mortality declined 43% from 1976-2020 in US (43% drop)
Single source65-year relative survival overall for ovarian cancer is 49.1% (2013-2019 SEER)
Verified7In 2022, 4,306 ovarian cancer deaths in UK women
Verified8Black women have 27% higher ovarian cancer mortality rate than white women (US)
Verified9Salpingo-oophorectomy reduces ovarian cancer risk by 80% in BRCA1 carriers
Directional10Opportunistic salpingectomy during benign hysterectomy reduces risk by 42%
Single source11Oral contraceptives reduce lifetime risk by 30-50% with 10+ years use
Verified12Risk-reducing salpingo-oophorectomy (RRSO) at age 35-40 reduces mortality 77% in BRCA2
Verified13Tubal ligation reduces mortality risk by 20-30%
Verified14Annual screening with TVUS + CA-125 does not reduce mortality (PLCO trial)
Directional15Aspirin/NSAIDs may lower mortality by 10-20% in observational studies
Single source16Hysterectomy reduces ovarian cancer risk by 30-40%
Verified17Multicomponent screening (MSSA) reduced mortality by 15% in UKCTOCS pilot
Verified18BRCA testing identifies 15-20% high-risk women, enabling prevention
Verified19Parity (3+ births) reduces risk and thus mortality impact by 30%
Directional20Breastfeeding reduces risk by 10-20% per year
Single source21Statins use associated with 30% lower ovarian cancer mortality
Verified22HPV vaccination not directly preventive but lifestyle factors matter
Verified23Genetic counseling uptake 50% among high-risk families
VerifiedMortality and Prevention Interpretation
Ovarian cancer remains a formidable killer, yet its mortality has impressively dropped by 43% since the 70s; we have powerful tools like surgery and birth control that can slash risk dramatically, but we still tragically lose nearly half of those diagnosed within five years, a burden disproportionately borne by Black women, all while knowing that better screening and wider uptake of genetic counseling could save countless more lives.
Risk Factors
1Having a first-degree relative with ovarian cancer increases risk 3- to 5-fold
Verified2BRCA1 mutation carriers have a 39-46% lifetime risk of ovarian cancer
Verified3Postmenopausal hormone therapy (estrogen-only) increases ovarian cancer risk by 24% with long-term use
Verified4Obesity (BMI ≥30) is associated with a 10% increased risk of ovarian cancer per 5-unit BMI increase
Directional5Endometriosis raises ovarian cancer risk 2- to 7-fold, particularly clear cell and endometrioid types
Single source6Talc use in genital area increases ovarian cancer risk by 20-30% in case-control studies
Verified7BRCA2 mutation confers a 10-27% lifetime ovarian cancer risk
Verified8Nulliparity (never having given birth) increases risk by 30-40%
Verified9Oral contraceptive use for 5+ years reduces ovarian cancer risk by 30%
Directional10Tubal ligation decreases ovarian cancer risk by 20%
Single source11Lynch syndrome (HNPCC) increases ovarian cancer risk to 8-12% lifetime
Verified12Smoking is linked to a 10-20% increased risk of mucinous ovarian tumors
Verified13Early age at menarche (<12 years) increases risk by 15-20%
Verified14Late age at menopause (>55 years) raises risk by 3% per year delay
Directional15Polycystic ovary syndrome (PCOS) is associated with 1.5-fold increased risk
Single source16Family history of breast cancer doubles ovarian cancer risk
Verified17Hormone replacement therapy (combined estrogen-progestin) for 5+ years increases risk by 10%
Verified18Infertility treatment with ovulation stimulants raises risk by 1.5-fold in some studies
Verified19Diabetes mellitus is linked to 15% higher ovarian cancer risk
Directional20High socioeconomic status correlates with 20% higher incidence in some populations
Single source21Breastfeeding for 12+ months reduces risk by 20%
Verified22PEER syndrome genes (PTEN, etc.) confer elevated risk
Verified23Alcohol consumption >14 drinks/week increases risk by 10% for certain subtypes
Verified24Physical inactivity (low activity) associated with 15% higher risk
Directional25Serous tubal intraepithelial carcinoma (STIC) as precursor in 70% of high-grade serous cases
Single source26Aspirin use may reduce risk by 10-20% with long-term use
Verified2770-80% of ovarian cancers are sporadic, 10-15% hereditary
VerifiedRisk Factors Interpretation
While heredity can load the genetic gun, lifestyle and reproductive history often pull the trigger, though a few prudent choices can surprisingly help to lower the hammer.
Treatment Outcomes
15-year survival for stage I ovarian cancer is 90-93%
Verified2Optimal cytoreduction (<1 cm residual) achieved in 75% of cases improves survival to 50 months median
Verified3Platinum-based chemotherapy response rate 70-80% in first-line
Verified4PARP inhibitors (olaparib) extend PFS by 7 months in BRCA+ maintenance (SOLO1 trial)
Directional5Bevacizumab adds 3.7 months PFS in first-line (GOG-0218)
Single source6Neoadjuvant chemotherapy allows optimal debulking in 40-50% initially unresectable
Verified7HIPEC (hyperthermic intraperitoneal chemo) improves survival by 12 months in stage III (OVHIPEC)
Verified810-year survival for localized ovarian cancer is 47.3% (SEER 2013-2019)
Verified9Dose-dense paclitaxel improves PFS by 4 months in Japanese trial
Directional10Secondary cytoreduction in platinum-sensitive recurrence yields 30-month median survival
Single source11Immunotherapy (pembrolizumab) ORR 8-10% in MSI-high ovarian ca
Verified12Intraperitoneal chemotherapy reduces mortality by 32% (GOG-172)
Verified13Mirvetuximab soravtansine ORR 31.7% in FRα+ platinum-resistant (MIRASOL)
Verified14Complete response to first-line therapy in 50-60% of high-grade serous cases
Directional15Rucaparib maintenance PFS 16.6 vs 5.4 months (ARIEL3)
Single source16Fertility-sparing surgery preserves fertility in 80% stage IA patients
Verified17CAR-T therapy shows promise with 40% response in preclinical
Verified18Trabectedin + pegylated liposomal doxorubicin PFS 7.3 months (OCEANS trial)
Verified195-year survival stage II is 70-75%
Directional20Niraparib maintenance HR 0.45 for PFS regardless of HRD status (PRIMA)
Single source21Whole pelvic radiation rarely used, local control 80% but poor OS
Verified22Upfront surgery OS 64 months vs 57 for neoadjuvant in EORTC trial
Verified23Denosumab reduces skeletal events by 18% in bone mets
Verified245-year survival stage IV is 17-20% (SEER)
DirectionalTreatment Outcomes Interpretation
The good news is we've built an impressive arsenal of tools that can win many battles against ovarian cancer, as seen in strong early-stage survival, but the sobering ten-year survival rate reveals we're still losing the war far too often.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4IARCiarc.who.intVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8GCOgco.iarc.who.intVisit source
- Reference 9CANCERcancer.caVisit source
- Reference 10CDCcdc.govVisit source
- Reference 11E-CANCERe-cancer.frVisit source
- Reference 12CANCERcancer.govVisit source
- Reference 13GCOgco.iarc.frVisit source
- Reference 14KREBSDATENkrebsdaten.deVisit source
- Reference 15AIOMaiom.itVisit source
- Reference 16ONKOLOGIAonkologia.org.plVisit source
- Reference 17BASSERbasser.orgVisit source
- Reference 18WHOwho.intVisit source
- Reference 19NATUREnature.comVisit source
- Reference 20MAYOCLINICmayoclinic.orgVisit source
- Reference 21ACOGacog.orgVisit source
- Reference 22ACCESSDATAaccessdata.fda.govVisit source
- Reference 23NEJMnejm.orgVisit source